Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: Investigations of mechanism

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  McDonnell, David P ^a   Detke, Holland C ^a   Bergstrom, Richard F ^b   Kothare, Prajakti ^a   Johnson, Jason ^a   Stickelmeyer, Mary ^a   Sanchez Felix, Manuel V ^a   Sorsaburu, Sebastian ^a   Mitchell, Malcolm I ^a  

^a ELI LILLY AND COMPANY   (United States)

^b F Bergstrom PK PD Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; OLANZAPINE PAMOATE; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; INJECTION SITE; MEDICAL INFORMATION; MEDICATION ERROR; POST INJECTION DELIRIUM SEDATION SYNDROME; SCHIZOPHRENIA; SYNDROME; DELAYED RELEASE FORMULATION; DRUG TOXICITY; INTOXICATION; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; STATISTICS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG TOXICITY; HUMANS; INJECTIONS, INTRAMUSCULAR; OVERDOSE; SCHIZOPHRENIA; SYNDROME; TREATMENT OUTCOME;

EID: 77953270958     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-45     Document Type: Article

References (22)

1. European Medicines Agency Assessment report for Zypadhera. 2008, European Medicines Agency., http://www.ema.europa.eu/humandocs/PDFs/EPAR/Zypadhera/H-890-en6.pdf
2. Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, Corya SA. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 2010, 10:43. 10.1186/1471-244X-10-43, 20537128.
3. Electronic Medicines Compendium Summary of product characteristics for ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection. 2009, Electronic Medicines Compendium., http://www.medicines.org.uk/emc/medicine/21361/SPC/ZYPADHERA
4. Shrewsbury R. Applied pharmaceutics in contemporary compounding. 2008, Englewood: Morton Publishing Company, 2.
5. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell DP. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010, 167:181-189. 10.1176/appi.ajp.2009.07081221, 20008947.
6. Martinez M, Rathbone M, Burgess D, Huynh M. In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release 2008, 129:79-87. 10.1016/j.jconrel.2008.04.004, 18514351.
7. Bergstrom R, Callaghan J, Cerimele J, Kurtz D, Hatcher B. Population pharmacokinetics and plasma concentrations of olanzapine. Olanzapine (Zyprexa): A novel antipsychotic 2000, 232-252. Philadelphia: Lippincott, Williams, and Wilkins, Tran P, Bymaster F, Tye N, Herra J, Breier A, Tollefson G.
8. Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG, Bergstrom RF. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 2009, 29:278-283. 10.1097/JCP.0b013e3181a289cb, 19440083.
9. Eli Lilly and Company Zyprexa [package insert]. 2009, Eli Lilly and Company.
10. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1995, 668:85-90. 10.1016/0378-4347(95)00061-M, 7550985.
11. Kurtz D, Bergstrom R, McDonnell DP, Mitchell M. Pharmacokinetics of multiple doses of olanzapine long-acting injection, an intramuscular formulation of olanzapine, in stabilized patients with schizophrenia [abstract]. Biol Psychiatry 2008, 63(suppl 1):288S.
12. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1987, 19:930-934.
13. Hamlin WE, Northam JI, Wagner JG. Relationship between in vitro dissolution rate and solubility of numerous compounds representative of various chemical species. J Pharm Sci 1965, 54:1651-1653.
14. Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001, 21:14-20. 10.1097/00004714-200102000-00004, 11199942.
15. Workman B. Safe injection techniques. Nurs Stand 1999, 13:47-53.
16. Downham TF, Cawley RA, Salley SO, Dal Santo G. Systemic toxic reactions to procaine penicillin G. Sex Transm Dis 1978, 5:4-9. 10.1097/00007435-197801000-00002, 417409.
17. Novocol Pharmaceuticals of Canada, Inc Septocaine with epinephrine [package insert]. 2005, Novocol Pharmaceuticals of Canada, Inc.
18. Institute for Safe Medication Practices ISMP medication safety alert: Bicillin products: syringe enhancements may help to prevent IV administration. 2004, Institute for Safe Medication Practices., http://www.ismp.org/Newsletters/acutecare/articles/20040506_2.asp
19. Institute for Safe Medication Practices ISMP medication safety alert: Action needed to prevent serious tissue injury with IV promethazine. 2006, Institute for Safe Medication Practices., http://www.ismp.org/Newsletters/acutecare/articles/20060810.asp
20. Sen S, Chini EN, Brown MJ. Complications after unintentional intra-arterial injection of drugs: Risks, outcomes, and management strategies. Mayo Clin Proc 2005, 80:783-795. 10.4065/80.6.783, 15945530.
21. Tang J, Weiter JJ. Branch retinal artery occlusion after injection of a long-acting risperidone preparation. Ann Intern Med 2007, 147:283-284.
22. Cummings JL, Barritt CF, Horan M. Delusions induced by procaine penicillin: case report and review of the syndrome. Int J Psychiatry Med 1986, 16:163-168.